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CONCLUSION: Influenza is not a benign disease. For
some infected patients, ER or hospital care is needed.
More aggressive and effective prevention and treatment
strategies may lead to cost avoidance via fewer influenza
related ER visits and hospitalizations.
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COST-EFFECTIVENESS OF ONCE-DAILY 
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AMOXYCILLIN/CLAVULANIC ACID IN THE 
TREATMENT OF ACUTE EXACERBATION OF 
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OBJECTIVE: Treatment for acute exacerbation of chronic
bronchitis (AECB) frequently consists of antimicrobial
therapy. The persistence of recurrent symptoms can lead
to substantial morbidity and increased healthcare costs.
These factors make it important to consider antimicro-
bial treatment from an economic as well as a clinical per-
spective. This study was designed to assess the relative ef-
fectiveness and cost of once-daily clarithromycin (CL
OD) 500 mg versus amoxycillin/clavulanic acid (AMCL)
625 mg TID in the treatment of AECB. 
METHODS: Of 250 patients enrolled in this investigator-
blind, multicenter, multicountry comparative trial of CL
OD and AMCL in adults with AECB, 127 were random-
ized to treatment with CL OD, and 123 with AMCL. The
primary measure of clinical effectiveness was response to
therapy. Healthcare resource utilization was monitored
from initiation of therapy to 19–23 days after the last study
medication. UK costs were applied to resource use aggre-
gated across all countries in the base case analysis. 
RESULTS: Investigator-defined clinical response rates
were similar in the clinically evaluable population (93/
106 [88%] CL OD and 85/99 [86%] AMCL, p  0.837).
Mean per patient costs were CL OD £120 (95% CI 6–234)
and AMCL £146 (95% CI 5–287). Mean length of stay
for hospitalized patients was 10.80 days for CL OD ver-
sus 15.25 days for AMCL. Both hospitalization costs and
study medication costs were lower for CL OD.
CONCLUSIONS: Previous studies have shown favorable
cost comparisons for CL OD versus AMCL but these
have been based on decision models. Results from this
study provide the first evidence of a trend of cost savings
for CL OD versus AMCL from a prospective random-
ized, multicountry trial.
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SAVINGS IN DIRECT MEDICAL COSTS 
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OBJECTIVE: Cystic fibrosis is a genetic disease in which
respiratory infections, usually due to Pseudomonas, are
the major cause of morbidity and mortality. A 20-week
double-blind placebo (P) controlled trial conducted in the
United States has shown that a new formulation of To-
bramycin (T) designed for jet nebulization and better tol-
erability produces significant improvements in pulmo-
nary function tests, as well as decreases in the concentra-
tions of Pseudomonas aeruginosa in sputum and a 26%
(95% CI 2–43%) decrease in the probability of being
hospitalized (Ramsey et al. NEJM 340:1;23–30, 1999). 
METHODS: Individual patient-data from the trial were
used to calculate the average number of days spent in
hospital, on home intravenous (IV) and oral antibiotic
therapy. Separate calculations were performed for the
subgroups of patients with FEV1 	50% of predicted and
FEV1 50% of predicted. To adjust for Canadian pric-
ing, pertinent economic parameters were obtained from
the Ontario and Quebec Ministries of Health. Usual care
data were obtained from a Delphi panel composed of the
medical directors of the cystic fibrosis clinics. 
RESULTS: Pertinent pharmacoeconomic results reported
in days and 95% CI were as follows: In hospital: T 
5.2, P  8.2; Dif  3 (5.02 to 0.97). Home IV ther-
apy: T  5.9, P  10.1; Dif.  3.1 (6.25 to 1.03).
Home oral therapy: T  15.4, P  18.1; Dif  2.7
(6.52 to 1.07). The average savings in direct medical
costs that could be produced by the use of T during a 20-
week treatment period in Quebec and Ontario would
amount to $10,802 per patient. A maximal saving of
$22,735 would be obtained in Ontario children with
FEV1 50% of predicted. A minimal saving of $4869
would correspond to Quebec adults with FEV1 50% of
predicted. 
CONCLUSIONS: Substantial savings in direct medical
costs could be obtained by using inhaled T to decrease
the rate of recurrent pulmonary infections in patients
with cystic fibrosis.
ECONOMIC AND OUTCOMES ISSUES OF 
ARTHRITIC DISEASE
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EFFICACY OF AN INTERVENTION TO 
RATIONALIZE PRESCRIBING OF 
NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS (NSAIDs)
Elkharrat D, Chastang C, Le Corre A, Caulin C
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NSAIDs are considered minor drugs in that their clinical
benefit is limited to reduction of symptoms. Although
they may be responsible for about 25% of side effects,
some of them fatal, most NSAIDs are prescribed for con-
troversial indications. An intervention was prospectively
